Table 4.
Clinical and hematological features of 495 patients within the IWG cohort classified according to the proposed entity of MDS with mutated SF3B1
| Patients, n (%) | |
|---|---|
| Sex | |
| Female | 212 (43) |
| Male | 283 (57) |
| Age (y) at sample, median (range) | 70 (11, 99) |
| <40 | 0 (0) |
| 40-49 | 10 (2) |
| 50-59 | 50 (10) |
| 60-69 | 115 (23) |
| 70-79 | 236 (48) |
| 80-89 | 79 (16) |
| ≥90 | 2 (<1) |
| Unknown | 3 (1) |
| WHO 2008 | |
| RARS | 238 (48) |
| RA/RCUD | 15 (3) |
| RCMD-RS | 156 (32) |
| RCMD | 17 (3) |
| Unknown | 68 (14) |
| IPSS-R | |
| Very low | 130 (26) |
| Low | 269 (54) |
| Intermediate | 21 (4) |
| High | 3 (1) |
| Very high | 0 (0) |
| Unknown | 72 (15) |
| IPSS-R cytogenetic risk group | |
| Very good | 26 (5) |
| Good | 415 (84) |
| Intermediate | 54 (11) |
| Poor | 0 (0) |
| Very poor | 0 (0) |
| Hemoglobin (g/dL), median (IQR) | 9.8 (8.7, 11.1) |
| <8.0 | 51 (10) |
| 8.0-9.99 | 216 (44) |
| 10.0-11.99 | 174 (35) |
| ≥12.0 | 19 (4) |
| Unknown | 35 (7) |
| ANC (×109/L), median (IQR) | 1.89 (0.9-3.6) |
| <0.5 | 4 (1) |
| 0.5-0.99 | 14 (3) |
| 1.0-1.8 | 49 (10) |
| ≥1.8 | 271 (55) |
| Unknown | 157 (32) |
| Platelets (×109/L), median (IQR) | 115 (56, 238) |
| <50 | 12 (2) |
| 50-100 | 12 (2) |
| 100-149 | 49 (10) |
| 150-449 | 290 (59) |
| ≥450 | 89 (18) |
| Unknown | 43 (9) |